High Grade Serous Ovarian Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

About 75% of epithelial ovarian malignancies are high-grade serous carcinomas, the most prevalent kind of ovarian cancer. Because it is the most prevalent kind of ovarian cancer, unless another type is indicated, it frequently serves as the default type in talks about ovarian cancer. Despite having a low incidence, ovarian cancer poses a serious public health risk due to its poor long-term survival rates, which have not much improved in recent years. It is more accurate to think of ovarian cancer as a spectrum of malignancies with varying histologies, clinical behaviours, and molecular-genetic characteristics.

Description

The most common type of ovarian cancer, high-grade serous carcinoma, accounts for about 75% of epithelial ovarian malignancies. It frequently serves as the default type in discussions about ovarian cancer because it is the most common type unless another type is indicated. It was once thought that ovarian malignancies started to develop in epithelium, the cells that line the surface of the ovaries. High-grade serous ovarian carcinoma (HGSOC) is a subtype of epithelial ovarian malignancies that also includes low-grade serous ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It is believed that the epithelium of the fallopian tubes is the site of origin for many cases of HGSOC. Frequently, high-grade serous carcinoma develops quickly. If it is frequently discovered in an advanced stage (Stage III or IV), this indicates that the cancer cells have already spread outside of the ovaries. Recent studies have shown that after developing as a primary tumor in the fallopian tubes, high-grade serous carcinomas take an average of 6.5 years to spread to the ovaries.

High Grade Serous Ovarian Cancer (Epidemiology)

Ovarian cancer continues to be the most lethal gynecological malignancy despite its low incidence, raising significant public health concerns. According to the WHO, ovarian cancer is the eighth most common type of cancer and the eighth leading cause of cancer death in women worldwide, with an estimated 225,500 cases being diagnosed and 140,200 patients dying each year.

High Grade Serous Ovarian Cancer -Current Market Size & Forecast Trends

The market for high-grade serous ovarian cancer (HGSOC) is projected to experience substantial growth, with the global ovarian cancer market estimated at approximately USD 2.44 billion in 2022 and expected to surpass USD 20.07 billion by 2032, reflecting a compound annual growth rate (CAGR) of 23.5% during this period. High-grade serous carcinoma, which accounts for about 70% of all ovarian cancer cases and nearly 80% of related deaths, is a significant driver of this market expansion. The increasing incidence of HGSOC, advancements in treatment options such as PARP inhibitors, and the development of personalized therapies are key factors contributing to this growth. North America is anticipated to dominate the market due to its advanced healthcare infrastructure and significant investments in research and development, while the Asia-Pacific region is expected to witness rapid growth due to improving healthcare access and rising awareness. Overall, the HGSOC market is well-positioned for robust expansion through 2035, supported by ongoing innovations in treatment and increasing patient awareness.

Despite having a low incidence, ovarian cancer poses a significant risk to the public's health because of its dismal long-term survival rates, which have not significantly increased in recent years. It is more accurate to think of ovarian cancer as a spectrum of malignancies with various histologies, clinical behaviors, and molecular-genetic characteristics. Of the various types, HGSOC is by far the most common and deadly. Since there are few early warning signs and vague symptoms, HGSOC is rarely found in its early stages. Recently, PARP inhibitors and antiangiogenic medications entered clinical use after demonstrating promise in prolonging progression-free survival in the most recent trials. Despite being long thought to be of ovarian origin, the majority of HGSOC cases are now thought to be caused by the secretory epithelial cells of the distal fallopian tube. Some of the leading companies that have the potential to propel the market upward include APR-246 (Aprea), Durvalumab (Celgene/MedImmune), Upifitamab rilsodotin (Adimab/Mersana Therapeutics), DCP 001 (DCPrime), and others.

Report Highlights

High Grade Serous Ovarian Cancer - Current Market Trends

High Grade Serous Ovarian Cancer - Current & Forecasted Cases across the G8 Countries

High Grade Serous Ovarian Cancer - Market Opportunities and Sales Potential for Agents

High Grade Serous Ovarian Cancer - Patient-based Market Forecast to 2035

High Grade Serous Ovarian Cancer - Untapped Business Opportunities

High Grade Serous Ovarian Cancer - Product Positioning Vis-a-vis Competitors' Products

High Grade Serous Ovarian Cancer - KOLs Insight